Rybelsus sales disappoint while Ozempic surpasses expectations at Novo Nordisk

Compared to last year, both Rybelsus and Ozempic generated more revenue in Q2.

by marketwire, translated by catherine brett

Published: 04.08.22 at 11:04

Novo Nordisk’s primary business area, dubbed Diabetes Care, fared worse than expected in the second quarter of 2022. The Ozempic drug once again generated higher-than-expected growth but Rybelsus disappointed compared to analyst estimates, the firm’s accounting report for the period showed Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

Ambu, Coloplast and GN helped by relaxation of China's covid policy

Protests in China have led to a relaxation in Covid-19 restrictions. | Foto: Thomas Peter

The three firms, which all have production facilities in the country, appear to be benefitting from the relaxation of China’s zero-tolerance Covid-19 policy.

Sonova completes Hysound Group acquisition, strengthens presence in China

Arnd Kaldowski, CEO of Sonova | Foto: Sonova / Pr

The hearing aid giant now owns over 200 hearing clinics in China.

Extra data boosts Lundbeck's agitation case

Foto: Thomas Borberg/Politiken/Ritzau Scanpix

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.